FULC241220C2000
- 1.77
- 0.000.00%
Fulcrum Therapeutics Newsroom
Fulcrum Therapeutics (NASDAQ:FULC) Shareholders Have Endured a 77% Loss From Investing in the Stock Three Years Ago
Subdued Growth No Barrier To Fulcrum Therapeutics, Inc. (NASDAQ:FULC) With Shares Advancing 32%
Fulcrum Therapeutics (FULC) Upgraded to Buy: Here's Why
Fulcrum Therapeutics to Participate in Upcoming December Conferences
Analysts' Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Fulcrum Therapeutics (FULC) and Immunic (IMUX)
Fulcrum Therapeutics Slides As Insider Purchases Lose Another US$362k
Oppenheimer Maintains Fulcrum Therapeutics(FULC.US) With Buy Rating, Maintains Target Price $14
RBC Capital Maintains Fulcrum Therapeutics(FULC.US) With Hold Rating, Maintains Target Price $4
Fulcrum Therapeutics Analyst Ratings
H.C. Wainwright Maintains Fulcrum Therapeutics(FULC.US) With Hold Rating, Maintains Target Price $4
Cautious Hold Rating on Fulcrum Therapeutics Amid Uncertain Prospects and Strategic Shifts
Fulcrum Therapeutics, Inc. (FULC) Q3 2024 Earnings Call Transcript Summary
Fulcrum Therapeutics, Inc. (FULC) Q3 2024 Earnings Call Transcript
Fulcrum Therapeutics GAAP EPS of -$0.35 Beats by $0.05
Fulcrum Therapeutics | 10-Q: Q3 2024 Earnings Report
Express News | Fulcrum Therapeutics Inc: Cash Runway Into at Least 2027
Express News | Fulcrum Therapeutics Q3 Operating Income USD -25.126 Million
Express News | Fulcrum Therapeutics Q3 Net Income USD -21.696 Million
Earnings Scheduled For November 13, 2024
Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference